宫颈癌术前新辅助化疗36例临床分析

目的：探讨平阳霉素／博来霉素联合顺铂（BP方案）、5-氟尿嘧啶＋异环磷酰胺联合顺铂（FIP方案）在宫颈癌新辅助化疗（Neoadjuvant Chemotherapy，NACT）的疗效及临床意义。方法：2004～2008年我院收治的Ib2-IIb期巨块型宫颈癌共62例，其中36例行BP或FIP方案化疗1～2个疗程后行根治性手术，为研究组；另26例直接行根治性手术，为对照组；术前评价NACT的疗效，并比较两组术中出血量、术后病理特征及并发症。结果：研究组36例患者术前进行NACT有效率为86％；术后病理检查示淋巴结阳性率，阴道切缘阳性率及宫旁累及率均较对照组低，差异有显著性。结论：利用BP，FIP方案对宫颈癌患者进行新辅助化疗有效、安全、经济，可缩小癌肿体积，增加手术切除率。

Clinical Effects of Neoadjuvant Chemotherapy on 36 Cases with Cervical Carcinoma

Objective： To observe the efficacy and safety on treating cervical cancer with neoadjuvant chemotherapy （NACT）. Methods： Thirty-six cases of Ⅰ b-Ⅱ b period bulky cervical cancer were treated by BP OR FIP during two cycles before operation, after chemotherapy they were treated by radical hysterectomy; 26 cases in the control group who underwent radical surgery directly. The blood loss during operation, pathological characteristics and surgical complications were compared between two groups. Results： After NACT, the therapeutic effective rate can obtain 86% , and all of sufferers can be treated by operation, the rate of lymphatic vascular space invasion was lower in NACT group. Conclusion： Clinical staging of Ⅰ b- Ⅱ b periodbulky cervical cancer can he depressed by untied chemotherapy of BP or FIP method before operation, at the same time, the the successful rate of operation can be raised.